相关实验视频

Updated: Jan 8, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

在治疗AML时,CD36单克隆抗体和Cytarabine之间的协同作用

Shuxin Huang¹, Dawei Chen², Yalin Luo²

¹School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China; Institute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou, China.

European journal of pharmacology

|December 15, 2025

概括

用单克隆抗体 (mAb) 与细胞因子 (Ara-C) 结合向CD36克服了急性髓性白血病 (AML) 的耐药性. 这种新的策略增强了AML细胞对Ara-C的敏感性,减少了瘤负担并改善了生存率.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

急性髓性白血病 (AML) 是一种具有挑战性的血液恶性瘤,由于药物耐药性,其结果不佳.
拾尸体受体CD36的高表达与AML复发和对化学疗法的耐药性相关,包括cytarabine (Ara-C).

研究的目的:

评估CD36向单克隆抗体 (mAb) 与AML治疗的Ara-C结合的治疗潜力.
调查抗CD36 mAb和Ara-C.之间的协同相互作用背后的分子机制.

主要方法:

评估了CD36表达和AML预后之间的关联.
评估了抗CD36 mAb (GZ1) 与Ara-C结合在体外和体内AML模型的疗效.
研究了IgG亚型和Fc介导功能在使用Fc沉默突变体的组合疗法的疗效中的作用.

主要成果:

高CD36表达与AML患者的预后不佳有关.
抗CD36 mAb GZ1和Ara-C的组合显著增加了AML细胞对Ara-C的敏感性.
在临床前AML模型中,组合疗法减少了瘤负担和延长了存活时间.
治疗疗效取决于IgG亚型 (IgG2a/IgG1>IgG3) 和Fc介导功能.

结论:

与Ara-C结合使用的Anti-CD36 mAb GZ1显示出针对AML的显著协同效应.
通过Fc介导的功能对于这种组合治疗的治疗结果的增强至关重要.
这种组合代表了一种有希望的新策略,以克服急性髓性白血病的耐药性.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 CD36 赛塔拉宾可以作为一种药物.单克隆抗体是一种单克隆抗体.

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...